Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relma-cel Secondary Infusion in r/r B-cell Lymphoma
NCT05806580Phase 4Recruiting
- Sponsor
- Ruijin Hospital
- Start
- May 2023
- Primary completion
- May 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of relmacabtagene autoleucel in malignant B-cell neoplasm, sponsored by Ruijin Hospital. Primary endpoint: Objective Response Rate at 3 months. Started May 2023; status: recruiting.
02
Drugs
relmacabtagene autoleucel
03
Conditions
malignant B-cell neoplasm
Beyond the preview
Go deeper on NCT05806580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05806580.